CNA/
Articles/
2510001949
  • Open Access
  • Review

Psychopathology and Psychiatric Risks Linked to High-Potency Cannabis, Crack Cocaine and Novel Psychoactive Substances

  • Tommaso Piro 1, *,   
  • Alessia Santeusanio 1,   
  • Federica Marsico 1,   
  • Arianna Rosati 1,   
  • Andrea Miuli 1,   
  • John Martin Corkery 2,   
  • Giovanni Martinotti 1, 2

Received: 01 Aug 2025 | Revised: 19 Aug 2025 | Accepted: 28 Oct 2025 | Published: 05 Nov 2025

Abstract

Background: High potency cannabis (HPC), crack cocaine, and novel psychoactive substances (NPS) have significantly reshaped the landscape of substance-related psychopathology. This transformation is driven both by the increased psychoactive potency of known substances and by the emergence of new synthetic compounds. The aim of this paper is to provide a practical clinical reference for settings lacking laboratory support. Methods: This study analyzes 69 articles published between 2015 and 2025, encompassing a total of 126,365 patients reporting symptoms associated with the use of HPC, crack, and NPS. Results: HPC is associated with an increased risk of acute and persistent psychosis, seems proportional link to THC concentration. Synthetic cannabinoids are also frequently associated with acute psychosis, hallucinations, and delusions. Cathinones are associated with psychotic symptomatology, while crack cocaine is primarily linked to mood disorders, depressive symptomatology, and suicidality. Discussion: Increasing THC concentrations in HPC appear to be associated with more severe psychotic manifestations, such as paranoia, aggression, and hallucinations. Synthetic cannabinoids can trigger auditory and visual hallucinations, underlining that stimulation of the endocannabinoid system can elicit pronounced psychotic symptomatology. Cathinones are also associated with psychotic symptomatology, with a more heterogeneous presentation, but can additionally induce alterations of vital parameters and elevated Creatine Phosphokinase (CPK) levels. Depressive symptomatology is predominant in crack cocaine use, while all substances under review demonstrate an association with anxiety symptoms. Conclusions: All three substance groups constitute a major and evolving challenge for mental health services. Distinctive symptom profiles can guide identification and evidence-based management in resource-limited settings.

References 

  • 1.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR); 5th Text Revision (DSM-5th-TR) ed.; American Psychiatric Publishing: Washington, DC, USA, 2022; ISBN 978-0-89042-575-6.
  • 2.
    Martinotti, G.; De Risio, L.; Vannini, C.; et al. Substance-Related Exogenous Psychosis: A Postmodern Syndrome. CNS Spectr. 2021, 26, 84–91. https://doi.org/10.1017/S1092852920001479.
  • 3.
    Vargas, G.; Shrier, L.A.; Chadi, N.; et al. High-Potency Cannabis Use in Adolescence. J. Pediatr. 2023, 252, 191–197.e1. https://doi.org/10.1016/j.jpeds.2022.07.034.
  • 4.
    Manthey, J.; Freeman, T.P.; Kilian, C.; et al. Public Health Monitoring of Cannabis Use in Europe: Prevalence of Use, Cannabis Potency, and Treatment Rates. Lancet Reg. Health-Eur. 2021, 10, 100227. https://doi.org/10.1016/j.lanepe.2021.100227.
  • 5.
    Hasbi, A.; Madras, B.K.; Bergman, J.; et al. Δ-Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons. iScience 2020, 23, 100794. https://doi.org/10.1016/j.isci.2019.100794.
  • 6.
    Urbi, B.; Sapaen, V.; Hughes, I.; et al. Effect of Cannabinoids on Glutamate Levels in the Human Brain: A Systematic Review and Meta-Analysis. J. Cannabis Res. 2025, 7, 21. https://doi.org/10.1186/s42238-025-00277-9.
  • 7.
    Di Forti, M.; Quattrone, D.; Freeman, T.P.; et al. The Contribution of Cannabis Use to Variation in the Incidence of Psychotic Disorder across Europe (EU-GEI): A Multicentre Case-Control Study. Lancet Psychiatry 2019, 6, 427–436. https://doi.org/10.1016/S2215-0366(19)30048-3.
  • 8.
    United Nations Office on Drugs and Labor. World Drug Report 2025 (Set of 3 Booklets), 1st ed.; World Drug Report; United Nations Research Institute for Social Development: Bloomfield, IA, USA, 2025; ISBN 978-92-1-154408-4.
  • 9.
    Roque Bravo, R.; Faria, A.C.; Brito-da-Costa, A.M.; et al. Cocaine: An Updated Overview on Chemistry, Detection, Biokinetics, and Pharmacotoxicological Aspects Including Abuse Pattern. Toxins 2022, 14, 278. https://doi.org/10.3390/toxins14040278.
  • 10.
    Verma, V. Classic Studies on the Interaction of Cocaine and the Dopamine Transporter. Clin. Psychopharmacol. Neurosci. Off. Sci. J. Korean Coll. Neuropsychopharmacol. 2015, 13, 227–238. https://doi.org/10.9758/cpn.2015.13.3.227.
  • 11.
    Perrenoud, L.O.; Oikawa, K.F.; Williams, A.V.; et al. Factors Associated with Crack-Cocaine Early Initiation: A Brazilian Multicenter Study. BMC Public Health 2021, 21, 781. https://doi.org/10.1186/s12889-021-10769-x.
  • 12.
    Rovaris, D.L.; Schuch, J.B.; Grassi-Oliveira, R.; et al. Effects of Crack Cocaine Addiction and Stress-Related Genes on Peripheral BDNF Levels. J. Psychiatr. Res. 2017, 90, 78–85. https://doi.org/10.1016/j.jpsychires.2017.02.011.
  • 13.
    Orsolini, L.; Chiappini, S.; Corkery, J.M.; The Use of New Psychoactive Substances (NPS) in Young People and Their Role in Mental Health Care: A Systematic Review. Expert Rev. Neurother. 2019, 19, 1253–1264. https://doi.org/10.1080/14737175.2019.1666712.
  • 14.
    Chiappini, S.; Mosca, A.; Miuli, A.; et al. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. Med. Kaunas Lith. 2021, 57, 580. https://doi.org/10.3390/medicina57060580.
  • 15.
    Wood, D.M.; Dargan, P.I. The Challenge of the Novel Psychoactive Substances: How Have We Responded and What Are the Implications of This Response? Br. J. Clin. Pharmacol. 2020, 86, 407–409. https://doi.org/10.1111/bcp.14236.
  • 16.
    Simão, A.Y.; Antunes, M.; Cabral, E.; et al. An Update on the Implications of New Psychoactive Substances in Public Health. Int. J. Environ. Res. Public. Health 2022, 19, 4869. https://doi.org/10.3390/ijerph19084869.
  • 17.
    Chiappini, S.; Vaccaro, G.; Mosca, A.; et al. New Trends of Drug Abuse in Custodial Settings: A Systematic Review on the Misuse of over-the-Counter Drugs, Prescription-Only-Medications, and New Psychoactive Substances. Neurosci. Biobehav. Rev. 2024, 162, 105691. https://doi.org/10.1016/j.neubiorev.2024.105691.
  • 18.
    Giorgetti, A.; Pascali, J.; Fais, P.; et al. Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications. Life 2021, 11, 440. https://doi.org/10.3390/life11050440.
  • 19.
    Daswani, R.R.; Choles, C.M.; Kim, D.D.; et al. A Systematic Review and Meta-Analysis of Synthetic Cathinone Use and Psychosis. Psychopharmacology 2024, 241, 875–896. https://doi.org/10.1007/s00213-024-06569-x.
  • 20.
    Nadal-Gratacós, N.; Pazos, M.D.; Pubill, D.; et al. Structure–Activity Relationship of Synthetic Cathinones: An Updated Review. ACS Pharmacol. Transl. Sci. 2024, 7, 2588–2603. https://doi.org/10.1021/acsptsci.4c00299.
  • 21.
    Schifano, F. Novel Psychoactive Substances (NPS): Clinical and Pharmacological Issues. Drugs Alcohol Today 2015, 15, 21–27. https://doi.org/10.1108/DAT-10-2014-0035.
  • 22.
    Bonaccorso, S.; Metastasio, A.; Ricciardi, A.; et al. Synthetic Cannabinoid Use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues. Brain Sci. 2018, 8, 133. https://doi.org/10.3390/brainsci8070133.
  • 23.
    Bond, B.W.; Duric, B.; Spinazzola, E.; et al. Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L’arrêt de l’utilisation Du Cannabis et Le Risque de Troubles Psychotiques: Une Analyse Cas-Témoins Tirée de l’étude Cas-Témoins EU-GEI WP2 Centrée Sur Les Premiers Épisodes Psychotiques. Can. J. Psychiatry Rev. Can. Psychiatr. 2025, 70, 182–193. https://doi.org/10.1177/07067437241290187.
  • 24.
    Drennan, M.L.; Karoly, H.C.; Bryan, A.D.; et al. Acute Objective and Subjective Intoxication Effects of Legal-Market High Potency THC-Dominant versus CBD-Dominant Cannabis Concentrates. Sci. Rep. 2021, 11, 21744. https://doi.org/10.1038/s41598-021-01128-2.
  • 25.
    Gibson, L.P.; Karoly, H.C.; Ellingson, J.M.; et al. Effects of Cannabidiol in Cannabis Flower: Implications for Harm Reduction. Addict. Biol. 2022, 27, e13092. https://doi.org/10.1111/adb.13092.
  • 26.
    Wang, G.S.; Buttorff, C.; Wilks, A.; et al. Impact of Cannabis Legalization on Healthcare Utilization for Psychosis and Schizophrenia in Colorado. Int. J. Drug Policy 2022, 104, 103685. https://doi.org/10.1016/j.drugpo.2022.103685.
  • 27.
    Dempster, E.L.; Wong, C.C.Y.; Burrage, J.; et al. Methylomic Signature of Current Cannabis Use in Two First-Episode Psychosis Cohorts. Mol. Psychiatry 2025, 30, 1277–1286. https://doi.org/10.1038/s41380-024-02689-0.
  • 28.
    Di Forti, M.; Marconi, A.; Carra, E.; et al. Proportion of Patients in South London with First-Episode Psychosis Attributable to Use of High Potency Cannabis: A Case-Control Study. Lancet Psychiatry 2015, 2, 233–238. https://doi.org/10.1016/S2215-0366(14)00117-5.
  • 29.
    Schoeler, T.; Ferris, J.; Winstock, A.R. Rates and Correlates of Cannabis-Associated Psychotic Symptoms in over 230,000 People Who Use Cannabis. Transl. Psychiatry 2022, 12, 369. https://doi.org/10.1038/s41398-022-02112-8.
  • 30.
    Mackie, C.J.; Wilson, J.; Freeman, T.P.; et al. A Latent Class Analysis of Cannabis Use Products in a General Population Sample of Adolescents and Their Association with Paranoia, Hallucinations, Cognitive Disorganisation and Grandiosity. Addict. Behav. 2021, 117, 106837. https://doi.org/10.1016/j.addbeh.2021.106837.
  • 31.
    Keller, C.J.; Chen, E.C.; Brodsky, K.; et al. A Case of Butane Hash Oil (Marijuana Wax)-Induced Psychosis. Subst. Abuse 2016, 37, 384–386. https://doi.org/10.1080/08897077.2016.1141153.
  • 32.
    Rossi, G.; Beck, M. A Little Dab Will Do: A Case of Cannabis-Induced Psychosis. Cureus 2020, 12, e10311. https://doi.org/10.7759/cureus.10311.
  • 33.
    van Amsterdam, J.; Vervloet, J.; de Weert, G.; et al. Acceptance of Pharmaceutical Cannabis Substitution by Cannabis Using Patients with Schizophrenia. Harm. Reduct. J. 2018, 15, 47. https://doi.org/10.1186/s12954-018-0253-7.
  • 34.
    Gorbenko, A.A.; Heuberger, J.A.A.C.; Juachon, M.; et al. CB1 Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial. Clin. Pharmacol. Ther. 2025, 117, 1427–1436. https://doi.org/10.1002/cpt.3581.
  • 35.
    Meier, M.H. Associations between Butane Hash Oil Use and Cannabis-Related Problems. Drug Alcohol Depend. 2017, 179, 25–31. https://doi.org/10.1016/j.drugalcdep.2017.06.015.
  • 36.
    Palmieri, B.; Laurino, C.; Vadalà, M. Spontaneous, Anecdotal, Retrospective, Open-Label Study on the Efficacy, Safety and Tolerability of Cannabis Galenical Preparation (Bedrocan). Int. J. Pharm. Pract. 2019, 27, 264–270. https://doi.org/10.1111/ijpp.12514.
  • 37.
    Roldan, L.; Sánchez-Gutiérrez, T.; Fernández-Arias, I.; et al. Cannabis Use and Cognitive Biases in People with First-Episode Psychosis and Their Siblings. Psychol. Med. 2024, 54, 4095–4105. https://doi.org/10.1017/S0033291724001715.
  • 38.
    Veras Eloy Santos, J.; Fonseca da Silva, N.A.; Marcolela Andreoli Sartes, L.; et al. Psychiatric and Obstetric Characteristics of Pregnant Crack Users Admitted to a Referral Center in Southern Brazil. J. Addict. Dis. 2023, 42, 481–90. https://doi.org/10.1080/10550887.2023.2279473.
  • 39.
    Mannes, Z.L.; Dunne, E.M.; Ferguson, E.G.; et al. Symptoms of Generalized Anxiety Disorder as a Risk Factor for Substance Use among Adults Living with HIV. AIDS Care—Psychol. Socio-Med. Asp. AIDSHIV 2021, 33, 623–632. https://doi.org/10.1080/09540121.2020.1808163.
  • 40.
    Hess, A.R.B.; de Almeida, R.M.M. Female Crack Cocaine Users under Treatment at Therapeutic Communities in Southern Brazil: Characteristics, Pattern of Consumption, and Psychiatric Comorbidities. Trends Psychiatry Psychother. 2019, 41, 369–374. https://doi.org/10.1590/2237-6089-2018-0089.
  • 41.
    Paiva, C.B.; Ferreira, I.B.; Lúcia Bosa, V.; et al. Depression, Anxiety, Hopelessness and Quality of Life in Users of Cocaine/Crack in Outpatient Treatment Depressão, Ansiedade, Desesperança e Qualidade de Vida Em Usuários de Cocaína/Crack Em Tratamento Ambulatorial. APRS Trends Psychiatry Psychother 2017, 9, 34–42.
  • 42.
    Feelemyer, J.; Dyer, T.V.; Turpin, R.E.; et al. Longitudinal Associations between the Disruption of Incarceration and Community Re-Entry on Substance Use Risk Escalation among Black Men Who Have Sex with Men; A Causal Analysis. Drug Alcohol Depend. 2020, 213, 10812.. https://doi.org/10.1016/j.drugalcdep.2020.108123.
  • 43.
    Tomko, C.; Nestadt, D.F.; Rouhani, S.; et al. Confirmatory Factor Analysis and Construct Validity of the Internalized Sex Work Stigma Scale among a Cohort of Cisgender Female Sex Workers in Baltimore, Maryland, United States. J. Sex Res. 2021, 58, 713–723. https://doi.org/10.1080/00224499.2020.1755821.
  • 44.
    Roglio, V.S.; Borges, E.N.; Rabelo-Da-Ponte, F.D.; et al. Prediction of Attempted Suicide in Men and Women with Crack-Cocaine Use Disorder in Brazil. PLoS ONE 2020, 15, e0232242. https://doi.org/10.1371/journal.pone.0232242.
  • 45.
    Jat, S.; Npj, P.; Zap, S. Use of Psychoactive Substances in Women in Outpatient Treatment. Rev. Bras. Enferm. 2019, 72, 178–183.
  • 46.
    Song, A.; Wenzel, S.L.; Cho, Y. Child Abuse Victimization, Depression, and Substance Use Among Homeless Women: Application of General Strain Theory. J. Interpers. Violence 2021, 36, 8852–8873. https://doi.org/10.1177/0886260519853410.
  • 47.
    Moccia, L.; Tofani, A.; Mazza, M.; et al. Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study. J. Psychoactive Drugs 2019, 51, 254–259. https://doi.org/10.1080/02791072.2019.1578444.
  • 48.
    Jones, L.; Reed, P.; Parrott, A. Mephedrone and 3,4-Methylenedioxy-Methamphetamine: Comparative Psychobiological Effects as Reported by Recreational Polydrug Users. J. Psychopharmacol. 2016, 30, 1313–1320. https://doi.org/10.1177/0269881116653106.
  • 49.
    Dolengevich-Segal, H.; Rodríguez-Salgado, B.; Gómez-Arnau, J.; et al. Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone. Case Rep. Psychiatry 2016, 2016, 8379562. https://doi.org/10.1155/2016/8379562.
  • 50.
    Brookman, F.; Bennett, T.H.; Hills, R. The Pleasures and Pains of Mephedrone Use: Perceptions of Users and Practitioners. Drugs Educ. Prev. Policy 2017, 24, 103–110. https://doi.org/10.1080/09687637.2016.1192106.
  • 51.
    Ordak, M.; Nasierowski, T.; Muszynska, E.; Bujalska-Zadrozny, M. The Psychiatric Characteristics of People on a Mephedrone (“Bath Salts”) Binge. Subst. Use Misuse 2020, 55, 1610–1617. https://doi.org/10.1080/10826084.2020.1753775.
  • 52.
    Severtsev, V.V.; Budanova, A.A. Recurrent Psychotic Episodes Induced by Synthetic Cathinones in a Monozygotic Twin with Drug Addiction: A Case Report. Consort. Psychiatr. 2023, 4, 58–65. https://doi.org/10.17816/CP13619.
  • 53.
    Beck, O.; Franzen, L.; Bäckberg, M.; et al. Involving MDPV in Sweden during 2010-2014: Results from the STRIDA Project. Clin. Toxicol. Phila. Pa 2015, 53, 865–873. https://doi.org/10.3109/15563650.2015.1089576.
  • 54.
    Beck, O.; Bäckberg, M.; Signell, P.; et al. Intoxications in the STRIDA Project Involving a Panorama of Psychostimulant Pyrovalerone Derivatives, MDPV Copycats. Clin. Toxicol. Phila. Pa 2018, 56, 256–263. https://doi.org/10.1080/15563650.2017.1370097.
  • 55.
    Diestelmann, M.; Zangl, A.; Herrle, I.; et al. MDPV in Forensic Routine Cases: Psychotic and Aggressive Behavior in Relation to Plasma Concentrations. Forensic Sci. Int. 2018, 283, 72–84. https://doi.org/10.1016/j.forsciint.2017.12.003.
  • 56.
    Daveluy, A.; Labadie, M.; Titier, K.; et al. Poisoning by Synthetic Cathinones: Consumption Behaviour and Clinicaldescription from 11 Cases Recorded by theAddictovigilance Centre of Bordeaux. Toxicol. Anal. Clin. 2017, 29, 34–40.
  • 57.
    Kapitány-Fövény, M.; Farkas, J.; Pataki, P.A.; et al. Novel Psychoactive Substance Use among Treatment-Seeking Opiate Users: The Role of Life Events and Psychiatric Symptoms. Hum. Psychopharmacol. 2017, 32, e2602. https://doi.org/10.1002/hup.2602.
  • 58.
    Kapitány-Fövény, M.; Kiss, A.; Farkas, J.; et al. Childhood Trauma, Cognitive Emotion Regulation and Motivation for Behavior Change Among Clients of Opioid Substitution Treatment With and Without Past Year Synthetic Cathinone Use During Therapy. Front. Neurosci. 2020, 14, 37. https://doi.org/10.3389/fnins.2020.00037.
  • 59.
    Blanco, G.; Vidler, D.; Roper, C.; et al. Acute Toxicity from the Synthetic Cathinone N-Ethylpentylone (Ephylone) in the United Kingdom. Clin. Toxicol. Phila. Pa 2021, 59, 1270–1273. https://doi.org/10.1080/15563650.2021.1909730.
  • 60.
    Costa, J.L.; Cunha, K.F.; Lanaro, R.; et al. Analytical Quantification, Intoxication Case Series, and Pharmacological Mechanism of Action for N-Ethylnorpentylone (N-Ethylpentylone or Ephylone). Drug Test. Anal. 2019, 11, 461–471. https://doi.org/10.1002/dta.2502.
  • 61.
    Zimmerman, L.; Kilwein, T.M.; Beyer, D.; et al. “Not for Human Consumption”: A Descriptive Investigation into User Characteristics, Motives, and Consequences Associated with Bath Salt Use. J. Psychoact. Drugs 2019, 51, 218–224. https://doi.org/10.1080/02791072.2019.1571652.
  • 62.
    John, M.E.; Thomas-Rozea, C.; Hahn, D. Bath Salts Abuse Leading to New-Onset Psychosis and Potential for Violence. Clin. Schizophr. Relat. Psychoses 2017, 11, 120–124. https://doi.org/10.3371/CSRP.JORO.061314.
  • 63.
    Schreck, B.; Guerlais, M.; Laforgue, E.; et al. Cathinone Use Disorder in the Context of Slam Practice: New Pharmacological and Clinical Challenges. Front. Psychiatry 2020, 11, 705. https://doi.org/10.3389/fpsyt.2020.00705.
  • 64.
    Chou, H.-H.; Hsieh, C.-H.; Chaou, C.-H.; et al. Synthetic Cathinone Poisoning from Ingestion of Drug-Laced “Instant Coffee Packets” in Taiwan. Hum. Exp. Toxicol. 2021, 40, 1403–1412. https://doi.org/10.1177/0960327121996043.
  • 65.
    Liakoni, E.; Müller, S.; Stoller, A.; et al. Presentations to an Urban Emergency Department in Bern, Switzerland Associated with Acute Recreational Drug Toxicity. Scand. J. Trauma Resusc. Emerg. Med. 2017, 25, 26. https://doi.org/10.1186/s13049-017-0369-x.
  • 66.
    Bäckberg, M.; Lindeman, E.; Beck, O.; et al. Characteristics of Analytically Confirmed 3-MMC-Related Intoxications from the Swedish STRIDA Project. Clin. Toxicol. Phila. Pa 2015, 53, 46–53. https://doi.org/10.3109/15563650.2014.981823.
  • 67.
    Weng, T.-I.; Chen, H.-Y.; Chin, L.W.; et al. Comparison of Clinical Characteristics between Meth/Amphetamine and Synthetic Cathinone Users Presented to the Emergency Department. Clin. Toxicol. Phila. Pa 2022, 60, 926–932. https://doi.org/10.1080/15563650.2022.2062376.
  • 68.
    Lin, C.-H.; Chen, J.-J.; Chan, C.-H. Comparison of Psychiatric and Clinical Profiles Between People Who Use Synthetic Cathinones and Methamphetamine: A Matched Case-Control Study. J. Clin. Psychopharmacol. 2023, 43, 122–130. https://doi.org/10.1097/JCP.0000000000001649.
  • 69.
    Paul, L.D.; Welter-Luedeke, J.; Penzel, S.; et al. Alpha-Pyrrolidinopentiothiophenone (α-PVT): A Forensic Case Study Including Plasma Concentrations. Forensic Sci. Int. 2021, 321, 110721. https://doi.org/10.1016/j.forsciint.2021.110721.
  • 70.
    Fujita, Y.; Mita, T.; Usui, K.; et al. Toxicokinetics of the Synthetic Cathinone α-Pyrrolidinohexanophenone. J. Anal. Toxicol. 2018, 42, e1–e5. https://doi.org/10.1093/jat/bkx080.
  • 71.
    Umebachi, R.; Aoki, H.; Sugita, M.; et al. Clinical Characteristics of α-Pyrrolidinovalerophenone (α-PVP) Poisoning. Clin. Toxicol. Phila. Pa 2016, 54, 563–567. https://doi.org/10.3109/15563650.2016.1166508.
  • 72.
    Crespi, C. Flakka-Induced Prolonged Psychosis. Case Rep. Psychiatry 2016, 2016, 3460849. https://doi.org/10.1155/2016/3460849.
  • 73.
    Winstock, A.; Lynskey, M.; Borschmann, R.; et al. Adam Winstock Michael Lynskey Rohan Borschmann Jon Waldron Risk of Emergency Medical Treatment Following Consumption of Cannabis or Synthetic Cannabinoids in a Large Global Sample. J. Psychopharmacol. 2015, 29, 698–703.
  • 74.
    Welter, S.; Lücke, C.; Lam, A.P.; et al. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study. Eur. Addict. Res. 2017, 23, 182–193. https://doi.org/10.1159/000479554.
  • 75.
    Besli, G.E.; Ikiz, M.A.; Yildirim, S.; et al. Synthetic Cannabinoid Abuse in Adolescents: A Case Series. J. Emerg. Med. 2015, 49, 644–650. https://doi.org/10.1016/j.jemermed.2015.06.053.
  • 76.
    Blevins, C.E.; Banes, K.E.; Stephens, R.S.; et al. A Preliminary Evaluation of Synthetic Cannabinoid Use among Adolescent Cannabis Users: Characteristics and Treatment Outcomes. Addict. Behav. 2016, 63, 114–119. https://doi.org/10.1016/j.addbeh.2016.07.005.
  • 77.
    Naviglio, S.; Papanti, D.; Moressa, V.; et al. An Adolescent with an Altered State of Mind. BMJ 2015, 350, h299. https://doi.org/10.1136/bmj.h299.
  • 78.
    Barceló, B.; Pichini, S.; López-Corominas, V.; et al. Acute Intoxication Caused by Synthetic Cannabinoids 5F-ADB and MMB-2201: A Case Series. Forensic Sci. Int. 2017, 273, e10–e14. https://doi.org/10.1016/j.forsciint.2017.01.020.
  • 79.
    Clayton, H.B.; Lowry, R.; Ashley, C.; et al. Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana. Pediatrics 2017, 139, e20162675. https://doi.org/10.1542/peds.2016-2675.
  • 80.
    Van Hout, M.C.; Hearne, E. User Experiences of Development of Dependence on the Synthetic Cannabinoids, 5f-AKB48 and 5F-PB-22, and Subsequent Withdrawal Syndromes. Int. J. Ment. Health Addict. 2016, 15, 565–579.
  • 81.
    Cohen, K.; Kapitány-Fövény, M.; Mama, Y.; et al. The Effects of Synthetic Cannabinoids on Executive Function. Psychopharmacology 2017, 234, 1121–1134. https://doi.org/10.1007/s00213-017-4546-4.
  • 82.
    Altintas, M.; Inanc, L.; Oruc, G.A.; et al. Clinical Characteristics of Synthetic Cannabinoid-Induced Psychosis in Relation to Schizophrenia: A Single-Center Cross-Sectional Analysis of Concurrently Hospitalized Patients. Neuropsychiatr. Dis. Treat. 2016, 12, 1893–1900. https://doi.org/10.2147/NDT.S107622.
  • 83.
    Ustundag, M.F.; Ozhan Ibis, E.; Yucel, A.; et al. Synthetic Cannabis-Induced Mania. Case Rep. Psychiatry 2015, 2015, 310930. https://doi.org/10.1155/2015/310930.
  • 84.
    Durand, D.; Delgado, L.L.; de la Parra-Pellot, D.M.; et al. Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use: A Case Report. Clin. Schizophr. Relat. Psychoses 2015, 8, 205–208. https://doi.org/10.3371/CSRP.DUDE.031513.
  • 85.
    Coppola, M.; Mondola, R. JWH-122 Consumption Adverse Effects: A Case of Hallucinogen Persisting Perception Disorder Five-Year Follow-Up. J. Psychoactive Drugs 2017, 49, 262–265. https://doi.org/10.1080/02791072.2017.1316431.
  • 86.
    Bloomfield, M.A.P.; Ashok, A.H.; Volkow, N.D.; et al. The Effects of Δ9-Tetrahydrocannabinol on the Dopamine System. Nature 2016, 539, 369–377. https://doi.org/10.1038/nature20153.
  • 87.
    Bossong, M.G.; van Berckel, B.N.; Boellaard, R.; et al. Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum. Neuropsychopharmacology 2009, 34, 759–766. https://doi.org/10.1038/npp.2008.138.
  • 88.
    Mayer, F.P.; Niello, M.; Bulling, S.; et al. Mephedrone Induces Partial Release at Human Dopamine Transporters but Full Release at Human Serotonin Transporters. Neuropharmacology 2023, 240, 109704. https://doi.org/10.1016/j.neuropharm.2023.109704.
  • 89.
    Baumann, M.H.; Partilla, J.S.; Lehner, K.R.; et al. Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products. Neuropsychopharmacology 2013, 38, 552–562. https://doi.org/10.1038/npp.2012.204.
  • 90.
    Gunasekera, B.; Diederen, K.; Bhattacharyya, S. Cannabinoids, Reward Processing, and Psychosis. Psychopharmacology 2022, 239, 1157–1177. https://doi.org/10.1007/s00213-021-05801-2.
  • 91.
    Tai, S.; Fantegrossi, W.E. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Curr. Addict. Rep. 2014, 1, 129–136. https://doi.org/10.1007/s40429-014-0014-y.
  • 92.
    Pepe, M.; Di Nicola, M.; Cocciolillo, F.; et al. 3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18F-FDG PET/CT Case Report. Pharmaceuticals 2024, 17, 452. https://doi.org/10.3390/ph17040452.
  • 93.
    Petrilli, K.; Ofori, S.; Hines, L.; et al. Association of Cannabis Potency with Mental Ill Health and Addiction: A Systematic Review. Lancet Psychiatry 2022, 9, 736–750. https://doi.org/10.1016/S2215-0366(22)00161-4.
  • 94.
    Rittiphairoj, T.; Leslie, L.; Oberste, J.-P.; et al. High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes: A Systematic Review. Ann. Intern. Med. 2025, 178, 1429–1440. https://doi.org/10.7326/ANNALS-24-03819.
  • 95.
    Lake, S.; Murray, C.H.; Henry, B.; et al. High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies. Am. J. Psychiatry 2025, 182, 616–638. https://doi.org/10.1176/appi.ajp.20240269.
  • 96.
    Dang, J.; Tao, Q.; Niu, X.; et al. Meta-Analysis of Structural and Functional Brain Abnormalities in Cocaine Addiction. Front. Psychiatry 2022, 13, 927075. https://doi.org/10.3389/fpsyt.2022.927075.
  • 97.
    Duncan, Z.; Ward, B.; Kippen, R.; et al. A Narrative Systematic Review of Associations and Temporality between Use of Methamphetamine, Ecstasy/MDMA, or Cocaine with Anxiety or Depressive Symptoms. Addict. Behav. 2024, 153, 107988. https://doi.org/10.1016/j.addbeh.2024.107988.
  • 98.
    Ricci, V.; Maina, G. Clinical and Public Health Challenge of Handling Synthetic Cathinone and Cannabinoid Abuse in Pediatric Care: A Narrative Review. Pediatr. Rep. 2025, 17, 19. https://doi.org/10.3390/pediatric17010019.
  • 99.
    Daziani, G.; Lo Faro, A.F.; Montana, V.; et al. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review. Int. J. Mol. Sci. 2023, 24, 6230. https://doi.org/10.3390/ijms24076230.
Share this article:
Download PDF
DOI
10.53941/cna.2025.100008
Issue
Volume 1, Issue 1
How to Cite
Piro, T.; Santeusanio, A.; Marsico, F.; Rosati, A.; Miuli, A.; Corkery, J. M.; Martinotti, G. Psychopathology and Psychiatric Risks Linked to High-Potency Cannabis, Crack Cocaine and Novel Psychoactive Substances. Clinical Neuropsychopharmacology and Addiction 2025, 1 (1), 8. https://doi.org/10.53941/cna.2025.100008.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2025 by the authors.